Investigators showed that the clinical development of resistance to mitogen-activated protein kinase inhibitors (MAPKi) was associated with reduced tumor expression of the melanoma suppressor autophagy and beclin 1 regulator 1 (AMBRA1) and that lower expression levels of AMBRA1 predicted a poor response to MAPKi treatment.
[Proceedings of The National Academy of Sciences of The United States of America]
